Search research articles
Contact Us
Filters
Showing results (181-190 of 213) with videos related to
Page
of 22
Sort By:
Nature
|
March 3, 2016
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma, Aparna H Kesarwala, Tobias Eggert, et al.
Journal of Translational Medicine
|
March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
David F Stroncek, Carolina Berger, Martin A Cheever, et al.
Blood Advances
|
December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia
Alexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.
Molecular Cancer Therapeutics
|
February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Alka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
Oncoimmunology
|
September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer
Lauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
JCI Insight
|
December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Journal for Immunotherapy of Cancer
|
June 28, 2017
Immunotherapy biomarkers 2016: overcoming the barriers
James L Gulley, Jay A Berzofsky, Marcus O Butler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Frontiers in Oncology
|
January 3, 2022
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Hoyoung M Maeng, Brittni N Moore, Hadi Bagheri, et al.
Blood
|
October 31, 2012
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program
Michael A Pulsipher, Pintip Chitphakdithai, Brent R Logan, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 213) with videos related to
Sort By:
Page
of 22
Nature
|
March 3, 2016
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma, Aparna H Kesarwala, Tobias Eggert, et al.
Journal of Translational Medicine
|
March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
David F Stroncek, Carolina Berger, Martin A Cheever, et al.
Blood Advances
|
December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia
Alexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.
Molecular Cancer Therapeutics
|
February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Alka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
Oncoimmunology
|
September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer
Lauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
JCI Insight
|
December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Journal for Immunotherapy of Cancer
|
June 28, 2017
Immunotherapy biomarkers 2016: overcoming the barriers
James L Gulley, Jay A Berzofsky, Marcus O Butler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Frontiers in Oncology
|
January 3, 2022
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Hoyoung M Maeng, Brittni N Moore, Hadi Bagheri, et al.
Blood
|
October 31, 2012
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program
Michael A Pulsipher, Pintip Chitphakdithai, Brent R Logan, et al.
Page
of 22